Certainty of genuine treatment increases drug responses among intellectually disabled patients

Neurology

Volumn 88, Issue 20, 2017, Pages 1912-1918

  Jensen, Karin B ^a   Kirsch, Irving ^b   Pontén, Moa ^a   Rosén, Annelie ^a   Yang, Kathy ^c   Gollub, Randy L ^c   Des Portes, Vincent ^d,e,f   Kaptchuk, Ted J ^b   Curie, Aurore ^d,e,f,g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d INSTITUT DES SCIENCES COGNITIVES   (France)

^e UNIVERSITÉ LYON 1   (France)

^f HOSPICES CIVILS DE LYON   (France)

^g Inserm   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

ARTICLE; DRUG RESPONSE; EFFECT SIZE; FRAGILE X SYNDROME; HUMAN; INTELLECTUAL IMPAIRMENT; MALE; NONHUMAN; OPEN STUDY; PLACEBO EFFECT; PRADER WILLI SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WILLIAMS BEUREN SYNDROME; INTELLECTUAL DISABILITY; META ANALYSIS; PSYCHOLOGY; UNCERTAINTY;

HUMANS; INTELLECTUAL DISABILITY; PLACEBO EFFECT; UNCERTAINTY;

EID: 85019830735     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003934     Document Type: Article

References (40)

1. Colloca L, Lopiano L, Lanotte M, Benedetti F. Overt versus covert treatment for pain, anxiety, and Parkinson?s disease. Lancet Neurol 2004; 3: 679-684
2. Finniss D, Kaptchuk T, Miller F, Benedetti F. Placebo effects: biological, clinical and ethical advances. Lancet 2010; 375: 686-695
3. American Psychiatric Association. Intellectual Disability 5th ed. Washington, DC: American Psychiatric Association; 2013
4. Curie A, Yang K, Kirsch I, et al. Placebo responses in genetically determined intellectual disability: a meta-analysis. PLoS One 2015; 10: e0133316
5. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009; 19: 34-40
6. Rochon PA, Binns MA, Litner JA, et al. Are randomized control trial outcomes influenced by the inclusion of a placebo group? A systematic review of nonsteroidal antiinflammatory drug trials for arthritis treatment. J Clin Epidemiol 1999; 52: 113-122
7. Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry 2014; 71: 1409-1421
8. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Hoboken: John Wiley & Sons 2009
9. Kaptchuk TJ. The double-blind, randomized, placebocontrolled trial: gold standard or golden calf?. J Clin Epidemiol 2001; 54: 541-549
10. Lidstone S, Schulzer M, Dinelle K, et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 2010; 67: 857-865
11. Picker JD, Walsh CA. New innovations: therapeutic opportunities for intellectual disabilities. Ann Neurol 2013; 74: 382-390
12. Sandler AD, Bodfish JW. Placebo effects in autism: lessons from secretin. J Dev Behav Pediatr 2000; 21: 347-350
13. Williams K, Wray JA, Wheeler DM. Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012: CD003495
14. Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA 2012; 307: 567-568
15. Montgomery GH, Kirsch I. Classical conditioning and the placebo effect. Pain 1997; 72: 107-113
16. Jensen KB, Kaptchuk TJ, Kirsch I, et al. Nonconscious activation of placebo and nocebo pain responses. Proc Natl Acad Sci USA 2012; 109: 15959-15964
17. Grelotti DJ, Kaptchuk TJ. Placebo by proxy. BMJ 2011; 343: d4345
18. Heller JH, Spiridigliozzi GA, Sullivan JA, Doraiswamy PM, Krishnan RR, Kishnani PS. Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial. Am J Med Genet A 2003; 116A: 111-116
19. Heller JH, Spiridigliozzi GA, Crissman BG, McKillop JA, Yamamoto H, Kishnani PS. Safety and efficacy of rivastigmine in adolescents with Down syndrome: longterm follow-up. J Child Adolesc Psychopharmacol 2010; 20: 517-520
20. Prasher VP, Adams C, Holder R; Down Syndrome Research Group. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer?s disease in adults with Down syndrome: open label study. Int J Geriatr Psychiatry 2003; 18: 549-551
21. Prasher VP, Fung N, Adams C. Rivastigmine in the treatment of dementia in Alzheimer?s disease in adults with Down syndrome. Int J Geriatr Psychiatry 2005; 20: 496-497
22. Spiridigliozzi GA, Heller JH, Crissman BG, et al. Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. Am J Med Genet A 2007; 143A: 1408-1413
23. Shapira NA, Lessig MC, Lewis MH, Goodman WK, Driscoll DJ. Effects of topiramate in adults with Prader-Willi syndrome. Am J Ment Retard 2004; 109: 301-309
24. Torrioli M, Vernacotola S, Setini C, et al. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A 2010; 152A: 1420-1427
25. Capone GT, Goyal P, Grados M, Smith B, Kammann H. Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. J Dev Behav Pediatr 2008; 29: 106-116
26. Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J. Risperidone in treating behavioural disturbances of Prader-Willi syndrome. Acta Psychiatr Scand 2000; 102: 461-465
27. Erickson CA, Wink LK, Ray B, et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology 2013; 228: 75-84
28. Hoybye C, Thoren M, Bohm B. Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome. J Intellect Disabil Res 2005; 49: 245-252
29. Festen DA, Wevers M, Lindgren AC, et al. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol 2008; 68: 919-925
30. Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, et al. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. J Clin Endocrinol Metab 2012; 97: 2307-2314
31. Miller JL, Angulo M. An open-label pilot study of Nacetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A 2014; 164A: 421-424
32. Erickson CA, Mullett JE, McDougle CJ. Open-label memantine in fragile X syndrome. J Autism Dev Disord 2009; 39: 1629-1635
33. Çaku A, Pellerin D, Bouvier P, Riou E, Corbin F. Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study. Am J Med Genet A 2014; 164A: 2834-2842
34. Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010; 10: 91
35. Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D. Effects of donepezil on cognitive functioning in Down syndrome. Am J Ment Retard 2003; 108: 367-372
36. Kishnani PS, Sommer BR, Handen BL, et al. The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. Am J Med Genet A 2009; 149A: 1641-1654
37. Kishnani PS, Heller JH, Spiridigliozzi GA, et al. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. Am J Med Genet A 2010; 152A: 3028-3035
38. Kondoh T, Kanno A, Itoh H, et al. Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial. Int J Psychiatry Med 2011; 41: 71-89
39. Prasher VP, Huxley A, Haque MS; Down Syndrome Ageing Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer?s disease: pilot study. Int J Geriatr Psychiatry 2002; 17: 270-278
40. Sahu JK, Gulati S, Sapra S, et al. Effectiveness and safety of donepezil in boys with fragile x syndrome: a doubleblind, randomized, controlled pilot study. J Child Neurol 2013; 28: 570-575